Thames Ventures VCT 2 plc (LSE:D467) commences share repurchases on September 30, 2022, under the program mandated by the shareholders in the Annual General Meeting held on September 27, 2022. As per the mandate, the company is authorized to repurchase up to 1,172,220 D shares, representing 14.9% of the issued D share capital; 1,667,628 DP67 shares representing approximately 14.9% of the issued DP67 share capital; 8,329,785 ventures shares representing 11.92% of the issued ventures share capital, 3,404,390 healthcare share representing 11.92% of the issued healthcare share capital of the company and 401,675 AIM shares representing approximately 14.9% of the issued AIM share capital of the company. The minimum price (exclusive of expenses) which may be paid for each ordinary share is 0.1p?

and the maximum price which may be paid for each ordinary share is the higher an amount equal to 105% of the average of the middle market quotations of the relevant share, as derived from the Daily Official List of the London Stock Exchange, for each of the five business days immediately preceding the day on which the share is contracted to be purchased and an amount equal to the higher of the price of the last independent trade of an ordinary share. Unless previously revoked or varied, the share repurchase program shall expire at the earliest of the conclusion of the next Annual General Meeting of the company in 2023 or on the expiry of 15 months from the passing of the resolution, whichever is the earlier. As of July 25, 2022, the company had 7,867,247 DSO D Shares, 11,192,136 DP67 Shares, 69,880,747 Ventures Shares, 28,560,321 Healthcare Shares and 2,695,803 AIM shares.